Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Cormorant Asset Management disclosed a new 5.8 million-share position in Erasca, an estimated $68.55 million purchase that was worth $93.84 million at quarter-end and represented 4.71% of the fund’s reportable assets. The filing signals continued institutional interest in a clinical-stage biotech that has rallied 715% over the past year, despite no approved products and a $183 million quarterly net loss. Erasca also reported about $409 million in cash and marketable securities, which management says should fund operations into the second half of 2028.

Analysis

The important signal here is not the headline-sized purchase itself, but who is buying it after a massive rerating and what that implies about the forward path of biotech capital. A specialist healthcare fund committing nearly 5% of reportable assets to a single pre-revenue oncology name suggests the market is still underpricing platform optionality and partner-validation effects, not just binary clinical readouts. That matters because in this segment, incremental institutional sponsorship can extend runway for a rerating well before commercialization.

The second-order effect is on comparables and capital allocation across the RAS/MAPK basket. If Erasca can sustain this momentum with clean safety data and combination partnerships, capital may rotate toward other platform-centric small caps with differentiated mechanisms and enough balance-sheet life to avoid dilution traps. Conversely, any stumble in efficacy translation or combo tolerability would likely hit the entire “precision oncology glue/inhibitor” trade, because these names are being priced more on narrative continuity than near-term cash flow.

The setup is fragile over a 1-3 month horizon despite the strong longer-dated balance sheet. The stock has already priced in a lot of good news, so the next leg requires either a clear clinical de-risking event or continued sponsor accumulation; absent that, biotech beta and profit-taking can compress multiples quickly. The real risk is not insolvency, but expectation fatigue: a delay, noisy data cut, or broader risk-off tape could unwind a significant portion of the recent rerating even if fundamentals remain intact.

The contrarian view is that the market may be overvaluing the optionality embedded in early signals while underweighting dilution risk from future trial expansion and the execution burden of multiple programs. Still, the presence of a large, informed buyer argues against chasing weakness aggressively; this is more attractive on a pullback or into a catalyst than after another vertical move.

Key Decisions for Investors

• Long ERAS on a 4-8 week dip-buying window; prefer entries after 5-10% pullbacks or post-catalyst consolidation. Risk/reward is attractive only if downside is capped by the cash runway story and upside comes from continued sponsor accumulation / data follow-through.
• Sell ERAS upside via call spreads into strength if the stock gaps on incremental positive headlines. The trade favors monetizing elevated implied volatility because the name is more likely to chop than trend cleanly after a 700%+ rerating.
• Pair trade: long ERAS / short a less differentiated, similarly valued early-stage oncology peer in the RAS/MAPK or platform oncology cohort. Goal is to isolate validation of a best-in-class narrative while reducing sector beta; time horizon 1-3 months.
• For risk-managed exposure, use ERAS call spreads or a small common-stock position ahead of catalyst windows rather than outright size. This preserves convexity while limiting drawdown if the market shifts from 'story' to 'proof.'
• Watch for confirmation in other biotech sponsors: if additional high-quality healthcare funds add to adjacent names, use that as a signal to rotate into the broader basket; if not, treat ERAS as a single-name momentum trade rather than a durable re-rating.